Etrolizumab: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 29: | Line 29: | ||
{{stub}} | {{stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 17:02, 22 March 2025
Etrolizumab is a monoclonal antibody designed for the treatment of Ulcerative colitis and Crohn's disease. It is developed by Genentech, a member of the Roche Group.
Mechanism of Action[edit]
Etrolizumab is a humanized monoclonal antibody that selectively binds to the beta7 subunit of the integrin heterodimer. This binding inhibits the interaction of the beta7 subunit with MAdCAM-1 and E-cadherin, thereby preventing the migration of leukocytes into gut tissues.
Clinical Trials[edit]
Etrolizumab has been studied in Phase III clinical trials for the treatment of moderate to severe ulcerative colitis and Crohn's disease. The results of these trials are pending.
Side Effects[edit]
The most common side effects of etrolizumab include nausea, headache, fatigue, and abdominal pain. Serious side effects can include infections, infusion reactions, and liver problems.
